Life Sciences Tools & Services · Nasdaq
ILMNIllumina, Inc.
- Last close
- $207.01 -1.2%
- 52-week range
- $112.65 to $309.35
- Market cap
- $31.3B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Below its 10-year median on all 4 multiples
Where each multiple sits today inside its own range since 2017, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-27. Every figure carries its unit.
Valuation
- P/E
- 35.6x
- Earnings yield
- 2.8%
- Price / sales
- 6.9x
- Price / book
- 10.0x
- Price / operating cash flow
- 25.4x
- EV / EBITDA
- 27.3x
- EV / sales
- 7.0x
- Free cash flow yield
- 3.4%
Profitability
- Gross margin
- 67.9%
- Operating margin
- 21.2%
- Net margin
- 19.7%
- Return on equity
- 28.5%
- Return on capital
- 16.5%
Growth per year
- Revenue, 3 years
- -1.8%
- Revenue, 5 years
- +6.0%
- Revenue, 9 years
- +6.8%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $1.34B
- Total debt
- $1.79B
- Net cash
- -$452M
- Debt / equity
- 0.57x
- Current ratio
- 2.63x
Shares and dividend
- Shares outstanding
- 151M
- Share count, 5 years
- +5.4%
- Beta, 1 year
- 1.08
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
Instruments went from 16% to 11% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Consumables | $3.23B | 74.3% | +2% |
| Services | $634M | 14.6% | -11% |
| Instruments | $482M | 11.1% | -4% |
Life Sciences Tools & Services peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $259B | +8% | 17.9% | 36.9x | 5.5x | 88th percentile |
| A Agilent Technologies, Inc. | $49.0B | +9% | 22.2% | 34.2x | 6.7x | 64th percentile |
| WAT Waters Corp | $45.2B | +81% | 4.7% | 198x | 8.1x | 90th percentile |
| IQV Iqvia Holdings Inc. | $43.7B | +9% | 12.8% | 32.2x | 2.5x | 38th percentile |
| MTD Mettler Toledo International Inc/ | $34.6B | +7% | n/a | 37.7x | 8.2x | 58th percentile |
| ILMN Illumina, Inc. | $31.3B | +6% | 21.1% | 35.6x | 6.9x | 25th percentile |
The company
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Founded
- 1998
- Headquarters
- San Diego, CA
- Fiscal year ends
- Late December
- Website
- illumina.com
What it does
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about ILMN.